Originally published as JCO Early Release 10.1200/JCO.2005.02.093 on November 15 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sihto, H. Articles by Joensuu, H. Search for Related Content PubMed PubMed Citation Articles by Sihto, H. Articles by Joensuu, H. Related Articles Related Article

KIT and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene Mutations and KIT Amplifications in Human Solid Tumors

From the Departments of Oncology and Pathology, Helsinki University Central Hospital, Helsinki; and Department of Oncology, Tampere University Hospital, Tampere, Finland

Address reprint requests to Heikki Joensuu, MD, Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, PO Box 180, FIN-00029 Helsinki, Finland; e-mail: heikki.joensuu{at}hus.fi

PURPOSE: Mutated KIT and platelet-derived growth factor receptor alpha (PDGFR) tyrosine kinases are the principal targets for imatinib mesylate in the treatment of gastrointestinal stromal tumors (GISTs). The frequency of activating KIT and PDGFRA gene mutations in most other histologic types of human cancer is not known.

MATERIALS AND METHODS: KIT exons 9, 11, 13, and 17 and PDGFRA exons 11 and 17 of 334 human cancers were screened for mutations using sensitive denaturing high-performance liquid chromatography (DHPLC). In addition, all KIT exons from 9 to 21 of 115 tumors were screened. Thirty-two histologic tumor types were examined. Samples with abnormal findings in DHLPC were sequenced. Immunostaining for the KIT protein (CD117) was performed in 322 (96.4%) of the 334 cases.

RESULTS: Of the 3,039 exons screened, only 17 had mutation. All 17 cases with either mutated KIT (n = 15) or PDGFRA (n = 2) were histologically GIST tumors, whereas none of the other histologic types of cancer (n = 316) harbored KIT or PDGFRA mutation. KIT immunostaining was rarely positive except in GISTs (18 of 18), small-cell lung cancer (10 of 30; 33%), and testicular teratocarcinoma (four of 17; 24%). Wild-type KIT gene amplification or chromosome 4 aneuploidy was common (seven of 12) in non-GIST tumors with strong KIT protein expression when studied with fluorescence in situ hybridization.

CONCLUSION: Despite frequent KIT protein expression in some tumor types, KIT and PDGFRA gene mutations are uncommon in most human cancers. Cancer KIT expression is frequently associated with multiple copies of the wild-type KIT gene.

Supported by grants from the Cancer Society of Finland, Foundation for the Finnish Cancer Institute, Helsinki University Research Grants, and the Sigrid Juselius Foundation.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Related Article

• Targeted Therapy With Imatinib: Hits and Misses?
  Margaret von Mehren
  JCO 2005 23: 8-10 [Full Text]

This article has been cited by other articles:

				K. S.M. Smalley, R. Contractor, T. K. Nguyen, M. Xiao, R. Edwards, V. Muthusamy, A. J. King, K. T. Flaherty, M. Bosenberg, M. Herlyn, et al. Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression Cancer Res., July 15, 2008; 68(14): 5743 - 5752. [Abstract] [Full Text] [PDF]

				M. Cristofanilli, P. Morandi, S. Krishnamurthy, J. M. Reuben, B.-N. Lee, D. Francis, D. J. Booser, M. C. Green, B. K. Arun, L. Pusztai, et al. Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations Ann. Onc., May 29, 2008; (2008) mdn352v1. [Abstract] [Full Text] [PDF]

				M. C. Heinrich, H. Joensuu, G. D. Demetri, C. L. Corless, J. Apperley, J. A. Fletcher, D. Soulieres, S. Dirnhofer, A. Harlow, A. Town, et al. Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases Clin. Cancer Res., May 1, 2008; 14(9): 2717 - 2725. [Abstract] [Full Text] [PDF]

				J. A. Gilbert, M. P. Goetz, C. A. Reynolds, J. N. Ingle, K. F. Giordano, V. J. Suman, H. E. Blair, R. B. Jenkins, W. L. Lingle, M. M. Reinholz, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy Mol. Cancer Ther., April 1, 2008; 7(4): 944 - 951. [Abstract] [Full Text] [PDF]

				J. Gibbons, M. J. Egorin, R. K. Ramanathan, P. Fu, D. L. Mulkerin, S. Shibata, C. H.M. Takimoto, S. Mani, P. A. LoRusso, J. L. Grem, et al. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group J. Clin. Oncol., February 1, 2008; 26(4): 570 - 576. [Abstract] [Full Text] [PDF]

				C. Jones, M. Rodriguez-Pinilla, M. Lambros, D. Bax, B. Messahel, G. M Vujanic, J. S Reis-Filho, and K. Pritchard-Jones c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours J. Clin. Pathol., November 1, 2007; 60(11): 1226 - 1231. [Abstract] [Full Text] [PDF]

				N. Holtkamp, N. Ziegenhagen, E. Malzer, C. Hartmann, A. Giese, and A. von Deimling Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme Neuro-oncol, July 1, 2007; 9(3): 291 - 297. [Abstract] [Full Text] [PDF]

				J. A. Curtin, K. Busam, D. Pinkel, and B. C. Bastian Somatic Activation of KIT in Distinct Subtypes of Melanoma J. Clin. Oncol., September 10, 2006; 24(26): 4340 - 4346. [Abstract] [Full Text] [PDF]

				C. A KOCH, O. GIMM, A. O VORTMEYER, H. K AL-ALI, P. LAMESCH, R. OTT, R. KLUGE, U. BIERBACH, and A. TANNAPFEL Does the Expression of c-kit (CD117) in Neuroendocrine Tumors Represent a Target for Therapy? Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 517 - 526. [Abstract] [Full Text] [PDF]

				T. Ishikubo, K. Akagi, M. Kurosumi, K. Yamaguchi, T. Fujimoto, H. Sakamoto, Y. Tanaka, and A. Ochiai Immunohistochemical and Mutational Analysis of c-kit in Gastrointestinal Neuroendocrine Cell Carcinoma Jpn. J. Clin. Oncol., August 1, 2006; 36(8): 494 - 498. [Abstract] [Full Text] [PDF]

				L Tornillo and L M Terracciano An update on molecular genetics of gastrointestinal stromal tumours. J. Clin. Pathol., June 1, 2006; 59(6): 557 - 563. [Abstract] [Full Text] [PDF]

				K. A. Kellar, M. V. Lorenzi, C. P. Ho, D. You, M.-L. Wen, R. P. Ryseck, S. Oppenheimer, B. E. Fink, G. D. Vite, B. R. Rowley, et al. Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics. Mol. Cancer Ther., June 1, 2006; 5(6): 1571 - 1576. [Abstract] [Full Text] [PDF]

				G. K. Dy, A. A. Miller, S. J. Mandrekar, M.-C. Aubry, R. M. Langdon Jr., R. F. Morton, S. E. Schild, J. R. Jett, and A. A. Adjei A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study Ann. Onc., November 1, 2005; 16(11): 1811 - 1816. [Abstract] [Full Text] [PDF]

				L. Karenko, S. Hahtola, S. Paivinen, R. Karhu, S. Syrja, M. Kahkonen, B. Nedoszytko, S. Kytola, Y. Zhou, V. Blazevic, et al. Primary Cutaneous T-Cell Lymphomas Show a Deletion or Translocation Affecting NAV3, the Human UNC-53 Homologue Cancer Res., September 15, 2005; 65(18): 8101 - 8110. [Abstract] [Full Text] [PDF]

				C. L. Corless, A. Schroeder, D. Griffith, A. Town, L. McGreevey, P. Harrell, S. Shiraga, T. Bainbridge, J. Morich, and M. C. Heinrich PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib J. Clin. Oncol., August 10, 2005; 23(23): 5357 - 5364. [Abstract] [Full Text] [PDF]

				M. von Mehren Targeted Therapy With Imatinib: Hits and Misses? J. Clin. Oncol., January 1, 2005; 23(1): 8 - 10. [Full Text] [PDF]